Tolperisone

Tolperisone

SCHEMBL5356342

[2H]Cc1ccc(C(=O)C(C)CN2CCCCC2)cc1

nearest known ligand 0.81

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM2 P08172 2/20 0.81
ADRA2B P18089 2/20 0.81
DRD3 P35462 2/20 0.81
SIGMAR1 Q99720 2/20 0.81
HRH3 Q9Y5N1 2/20 0.81
ALDH1A1 P00352 4/20 0.79
LMNA P02545 3/20 0.79
CYP2D6 P10635 1/20 0.68
ADRA2C P18825 1/20 0.68
CHRM3 P20309 1/20 0.68
OPRD1 P41143 1/20 0.68
KCNH2 Q12809 1/20 0.68
SLC6A4 P31645 4/20 0.52
NTSR1 P30989 1/20 0.46
MITF O75030 2/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
HTT P42858 1/20 0.46
RAB9A P51151 1/20 0.46
GFER P55789 1/20 0.46
PAX8 Q06710 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Deutolperisone SCHEMBL5371621 0.91 CHRM2 (0.81) CHRM2ADRA2BDRD3SIGMAR1HRH3
Tolperisone SCHEMBL17223884 0.90 CHRM2 (1.00) CHRM2ADRA2BDRD3SIGMAR1HRH3
Tolperisone SCHEMBL148499 0.90 CHRM2 (1.00) CHRM2ADRA2BDRD3SIGMAR1HRH3
Tolperisone SCHEMBL4780118 0.90 CHRM2 (1.00) CHRM2ADRA2BDRD3SIGMAR1HRH3
Tolperisone SCHEMBL4516510 0.90 CHRM2 (1.00) CHRM2ADRA2BDRD3SIGMAR1HRH3
SCHEMBL21451092 0.90 CHRM2 (1.00) CHRM2ADRA2BDRD3SIGMAR1HRH3
Tolperisone SCHEMBL872770 0.88 ALDH1A1 (1.00) CHRM2ADRA2BDRD3SIGMAR1HRH3
SCHEMBL9172663 0.88 CHRM2 (0.97) CHRM2ADRA2BDRD3SIGMAR1HRH3
Tolperisone SCHEMBL15663055 0.87 CHRM2 (0.94) CHRM2ADRA2BDRD3SIGMAR1HRH3
SCHEMBL10852535 0.84 CHRM2 (0.78) CHRM2ADRA2BDRD3SIGMAR1HRH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7307091-B2 Deuterated 3-piperidinopropiophenone and medicaments containing said compounds BDD BEROLINA DRUG DEVELOPMENT GMBH (DE) 2007-12-11 US disclosed
EP-1383752-B1 DEUTERATED 3-PIPERIDINOPROPIOPHENONE AND MEDICAMENTS CONTAINING SAID COMPOUNDS TURICUM DRUG DEV AG (CH) 2005-06-22 EP disclosed
US-20040186136-A1 Deuterated 3-piperidinopropiophenone and medicaments containing said compounds BDD BEROLINA DRUG DEVELOPMENT GMBH (DE) 2004-09-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040186136-A1 Deuterated 3-piperidinopropiophenone and medicaments containing said compounds MUSK, CPT1B, PYGM CHRM2 1882/4885ADRA2B 250/4885DRD3 128/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.